Human induced pluripotent stem cells (iPSCs) have the capability of revolutionizing research and therapy of liver diseases by providing a source of hepatocytes for autologous cell therapy and disease modelling. However, despite progress in advancing the differentiation of iPSCs into hepatocytes (iPSC-Heps) in vitro 1-3 , cells that replicate the ability of human primary adult hepatocytes (aHeps) to proliferate extensively in vivo have not been reported. This deficiency has hampered efforts to recreate human liver diseases in mice, and has cast doubt on the potential of iPSC-Heps for liver cell therapy. The reason is that extensive post-transplant expansion is needed to establish and sustain a therapeutically effective liver cell mass in patients, a lesson learned from clinical trials of aHep transplantation 4 . Here, as a solution to this problem, we report the generation of human fibroblast-derived hepatocytes that can repopulate mouse livers. Unlike current protocols for deriving hepatocytes from human fibroblasts, ours did not generate iPSCs but cut short reprogramming to pluripotency to generate an induced multipotent progenitor cell (iMPC) state from which endoderm progenitor cells and subsequently hepatocytes (iMPC-Heps) could be efficiently differentiated. For this purpose we identified small molecules that aided endoderm and hepatocyte differentiation without compromising proliferation. After transplantation into an immune-deficient mouse model of human liver failure, iMPC-Heps proliferated extensively and acquired levels of hepatocyte function similar to those of aHeps. Unfractionated iMPC-Heps did not form tumours, most probably because they never entered a pluripotent state. Our results establish the feasibility of significant liver repopulation of mice with human hepatocytes generated in vitro, which removes a longstanding roadblock on the path to autologous liver cell therapy.
Human induced pluripotent stem cells (iPSCs) have the capability of revolutionizing research and therapy of liver diseases by providing a source of hepatocytes for autologous cell therapy and disease modelling. However, despite progress in advancing the differentiation of iPSCs into hepatocytes (iPSC-Heps) in vitro [1] [2] [3] , cells that replicate the ability of human primary adult hepatocytes (aHeps) to proliferate extensively in vivo have not been reported. This deficiency has hampered efforts to recreate human liver diseases in mice, and has cast doubt on the potential of iPSC-Heps for liver cell therapy. The reason is that extensive post-transplant expansion is needed to establish and sustain a therapeutically effective liver cell mass in patients, a lesson learned from clinical trials of aHep transplantation 4 . Here, as a solution to this problem, we report the generation of human fibroblast-derived hepatocytes that can repopulate mouse livers. Unlike current protocols for deriving hepatocytes from human fibroblasts, ours did not generate iPSCs but cut short reprogramming to pluripotency to generate an induced multipotent progenitor cell (iMPC) state from which endoderm progenitor cells and subsequently hepatocytes (iMPC-Heps) could be efficiently differentiated. For this purpose we identified small molecules that aided endoderm and hepatocyte differentiation without compromising proliferation. After transplantation into an immune-deficient mouse model of human liver failure, iMPC-Heps proliferated extensively and acquired levels of hepatocyte function similar to those of aHeps. Unfractionated iMPC-Heps did not form tumours, most probably because they never entered a pluripotent state. Our results establish the feasibility of significant liver repopulation of mice with human hepatocytes generated in vitro, which removes a longstanding roadblock on the path to autologous liver cell therapy.
Current protocols for directed hepatocyte differentiation of iPSCs (or human embryonic stem cells; ESCs) produce cells that express many functions of human primary adult hepatocytes (aHeps) [1] [2] [3] . Some functions of iPSC/ESC-Heps, such as cytochrome P450 (CYP450) enzyme expression, are underdeveloped, whereas others, such as albumin (ALB) synthesis, are near normal. Human serum ALB (HSA) levels have therefore been used to follow the fate and measure the expansion of iPSC/ESC-Heps transplanted into mice. Since the advent of protocols for hepatocyte differentiation of iPSCs/ESCs, numerous results from transplantation of these cells into mice have been reported. All of these studies, even those in which transplanted iPSC/ESC-Heps had a growth advantage, failed to reach HSA levels above 2 mg ml 21 (refs 5-7) , which is more than 1,000-fold lower than what has been achieved with aHeps 8 and in our experience reflects less than 0.05% liver repopulation (data not shown). These disappointing results have been largely attributed to failure of iPSC/ESC-Heps to proliferate after transplantation.
Reprogramming of somatic cells to a stable pluripotent state followed by differentiation into another cell type is a complicated process.
Alternatively, the developmentally plastic state established soon after overexpression of the reprogramming factors can be harnessed for lineage conversion. Using this approach we and others previously induced human fibroblasts to assume a multipotent progenitor cell (iMPC) state that allowed efficient differentiation into myeloid 9 or smooth muscle and endothelial cells 10, 11 . Because these iMPC derivatives could proliferate extensively, we reasoned that this method could be used to generate hepatocytes that were not compromised by growth arrest.
To investigate this possibility we transduced 10 4 human fibroblasts with retroviruses expressing OCT4, SOX2 and KLF4 (ref. 12) and replated them for reprogramming into endoderm in medium containing established growth factors and the small molecule CHIR99021 (CHIR) 1-3 ( Fig. 1 ). Only 14 days later, we detected expression of the endodermspecific genes SOX17 and FOXA2 by quantitative PCR with reverse transcription (qRT-PCR) (Extended Data Fig. 1a ). While only about 20 SOX17-positive and FOXA2-positive colonies formed under these 1 
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Reprogramming Hepatocyte specification T r a n s d u c t io n R e p la t in g 2 d a y s C o lo n y s e le c t io n T r a n s p la n t 3 days 7 days conditions, exposing the cells to additional small molecules known to promote reprogramming 13, 14 increased the number of colonies to more than 80 (Extended Data Fig. 1b-d and Supplementary Table 1 ). Next we investigated whether de novo endoderm differentiation was preceded by a pluripotent state. We found no expression of the pluripotency-specific genes OCT4 and NANOG even at the earliest stages of the reprogramming process (Extended Data Fig. 1e ). Because avoiding a pluripotent state decreases the cells' tumour risk, we confirmed this result by TRA-1-60 (ref. 15 ) flow cytometry at the end of the reprogramming process (Extended Data Fig. 1f, g ). In addition we monitored cultures undergoing reprogramming for FOXA2-positive cells, referred to as iMPC-derived endoderm progenitor cells (iMPC-EPCs), and NANOG-positive cells by immunostaining and flow cytometry (Extended Data Fig. 2a ). We found FOXA2-positive cells as early as 16 days after initiating reprogramming, whereas NANOG-positive cells were always absent (Extended Data Fig. 2b-d ). We also used doxycycline-inducible lentiviruses expressing OCT4, SOX2 and KLF4 to compare the dynamics of reprogramming to endoderm versus pluripotency (Extended Data Fig. 3a ). We detected iMPC-EPC colonies in transduced cultures grown under iMPC-EPC reprogramming conditions for 21 days after only 7 days of treatment with doxycycline. In contrast, generation of iPSCs required treating the cultures with doxycycline for 14 days and growing them under iPSC reprogramming conditions for 30 days (Extended Data Fig. 3b ). Our findings that human fibroblasts reprogram into iMPC-EPCs faster than into iPSCs and without expressing pluripotency markers show that our protocol does not produce a pluripotent intermediate stage, which confirms previous results from shortcutting reprogramming to pluripotency for lineage conversion [9] [10] [11] .
We also determined whether iMPC-EPCs could be expanded in vitro, a prerequisite for producing the large quantities needed for human liver cell therapy. We found that combining CHIR with A83-01 (A83) 16 increased iMPC-EPC colony size ( Fig. 1 and Extended Data Fig. 4a ). The addition of epidermal growth factor and basic fibroblast growth factor caused further expansion and facilitated passaging for more than 25 times, producing more than 10 16 iMPC-EPCs from a single colony ( Fig. 2a , b, Extended Data Fig. 4b and Supplementary Table 1 ). These cells showed high viability after cryopreservation (data not shown).
Expanding iMPC-EPCs maintained endoderm differentiation, as demonstrated by positive immunostaining for FOXA2 and SOX17 and negative immunostaining for NANOG ( Fig. 2a and Extended Data Fig. 4c ). Expanding iMPC-EPCs acquired hepatocyte nuclear factor 4a (HNF4a) expression ( Fig. 2a and Extended Data Fig. 4d ), suggesting further specification. To define their stage of differentiation, we compared iMPC-EPCs with ESC-derived definitive endoderm cells (DECs) and primitive gut-tube endoderm cells (GECs) 17 (Fig. 2c ). We found that iMPC-EPCs resembled ESC-GECs, except for a lack of OCT4 and NANOG gene expression. iMPC-EPCs also lacked expression of the ectoderm-specific and mesoderm-specific genes PAX6 and BRY, suggesting commitment to endoderm differentiation. Further analyses showed that iMPC-EPCs had a propensity for differentiating into liver and pancreas but not into lung or intestine (Extended Data Fig. 4e , f and data not shown). These results establish the feasibility of using human fibroblasts to generate endoderm cells that share many characteristics with previously reported ESC/iPSC-derived endodermal progenitor cell lines 18 , but seem more lineage restricted and never entered a pluripotent state.
To further differentiate iMPC-EPCs into iMPC-Heps, we cultured them in medium containing factors that have been reported to drive the hepatic differentiation of iPSC-DECs 1,3 ( Fig. 1 ). These factors were effective in inducing expression of the fetal hepatocyte marker a-fetoprotein, but few cells expressed the more mature markers ALB and a 1 -antitrypsin (AAT) (Extended Data Fig. 5a ). To improve hepatocyte differentiation, we screened small molecules for inducers of ALB gene expression, of which A83 and the Notch inhibitor Compound E 16 were effective (Extended Data Fig. 5b ). Because transforming growth factor-b and Notch signalling direct bipotential embryonic liver progenitor cells towards a biliary fate 19, 20 , our results suggest that inhibiting biliary differentiation promotes hepatocyte differentiation. 
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Like aHeps, iMPC-Heps were polygonal, were occasionally binucleate, and expressed the hepatocyte markers HNF4a, ALB, AAT and cytokeratin 18 ( Fig. 3a) . iMPC-Heps also showed hepatocyte functions such as glycogen storage, lipid uptake and storage, and urea production (Extended Data Fig. 6a, b ). Gene expression analysis showed that iMPC-Heps generally resembled human primary fetal hepatocytes (fHeps) (Fig. 3b ), although some cells were less differentiated ( Fig. 3c and Supplementary Table 1 ). Analysis of ALB secretion and CYP450 activities confirmed that iMPC-Heps were less mature than aHeps, but also showed that iMPC-Heps were more differentiated than iPSC-Heps generated as reported previously 1, 3 (Fig. 3d , e and Extended Data Fig. 6c ). The medium used for iMPC-EPC/Hep generation did not produce iPSC-Heps with improved function, which underscores the importance of reprogramming-induced developmental plasticity in this process (Extended Data Fig. 6d ).
To test whether iMPC-Heps can expand after transplantation, we transplanted 10 6 cells into FRG mice, an immune-deficient mouse model of human tyrosinaemia type I (ref. 8) . The liver injury caused by this disease creates a growth advantage for differentiated hepatocytes but not for immature liver progenitor cells. Liver repopulation of FRG mice therefore requires both mature hepatocyte function and the ability to proliferate. To detect expansion of the transplanted iMPC-Heps, we measured HSA levels monthly for more than nine months. The earliest we could detect HSA was two months after transplantation ( Fig. 4a ), when levels were at most 140 ng ml 21 , but they increased continuously, reaching levels of up to 104 mg ml 21 six months later. By this time, HSA levels were tenfold higher in control FRG mice transplanted with 10 6 aHeps. The delayed onset but parallel upward trend of HSA levels in iMPC-Hep-transplanted mice, in comparison with control mice, suggested that iMPC-Heps were inferior to aHeps in engraftment efficiency and the need for post-transplant maturation, but not in the ability to proliferate. Indeed, we found that although iMPC-Heps generated significantly fewer repopulating nodules than aHeps (data not shown), these nodules grew markedly between three and nine months after transplantation (Extended Data Fig. 7a ). Moreover, iMPC-Heps still proliferated nine months after transplantation ( Fig. 4b ). So far we have observed a maximum nodule size of 4,000 iMPC-Heps and a liver repopulation level of 2% (Extended Data Fig. 7b , c).
To determine whether iMPC-Heps matured after transplantation, we compared the global gene expression profiles of transplanted iMPC-Heps and aHeps. For this purpose we isolated nodules of iMPC-Heps and aHeps by laser-capture microscopy (Extended Data Fig. 7d , e) and analysed their RNA with microarrays. We found that iMPC-Heps and aHeps clustered closely together-very few genes were differentially expressed, none of which were of known importance for hepatocyte function ( Table 2 ). We also compared cultured iMPC-Heps and freshly isolated aHeps, and found marked differences in gene expression between these two cell types, which illustrates the extensive maturation that iMPC-Heps underwent after transplantation. In fact, before transplantation, the gene expression profile of iMPC-Heps resembled that of iPSC-Heps. We confirmed the microarray results by qRT-PCR and immunostaining ( Fig. 4d and Extended Data Fig. 9a-c ). In addition we determined whether maturation of gene expression translated into normal function by measuring debrisoquine hydroxylation-a unique function of human hepatocytes executed by CYP2D6 (ref. 21)-in mice repopulated to similar levels with iMPC-Heps or aHeps. We found no difference in plasma 4-hydroxy-debrisoquine levels between these mice, which shows that CYP2D6 underwent maturation in iMPC-Heps from negligible expression levels in vitro to normal activity in vivo (Figs 3b and 4e). In accord with a need for post-transplant maturation of iMPC-Heps, which is reminiscent of iPSC/ESC-derived pancreatic b-cells 22 , we found that iMPC-Hep transplantation improved the survival of mice with chronic liver failure, but not that of those with acute liver failure (Extended Data Fig. 10a, b ).
Finally, we ruled out fusion with mouse hepatocytes as the reason for post-transplant maturation and proliferation of iMPC-Heps (Fig. 4f) , and investigated the origin of dysplastic nodules observed in some iMPC-Hep and aHep recipients (Extended Data Fig. 10c ). Absence of differentiation-independent, human-specific b 2 -microglobulin expression showed that these nodules originated from mouse cells, thus representing a known complication of tyrosinaemia type I (Extended Data Fig. 10d ) 23 .
Our results show that iMPC-Heps are not affected by limitations of iPSC/ESC-Heps generated with current protocols, particularly deficiencies in in vivo efficacy and safety. Although many aspects of iMPC-Hep generation and transplantation remain to be explored and improved, the fact that these cells can fully mature and proliferate for months after . c, Flow cytometry shows that most iMPC-Heps express ALB, HNF4a and CK18. d, ELISA shows significant ALB secretion by iMPC-Heps in comparison with parental fibroblasts, iPSC-Heps and aHeps. Results are means and s.e.m. for biological replicates (n 5 3); Student's t-test, two asterisks, P , 0.01. e, Quantification of the activities of the CYP3A family (assay selectivity CYP3A5 $ CYP3A7 . CYP3A4), CYP3A4 and CYP2C19 shows higher levels in iMPC-Heps than in iPSC-Heps. Parental fibroblasts and aHeps were used as a negative and positive control, respectively. LCU, luminescent counting units. Results are means and s.e.m. for biological replicates (n 5 3); Student's t-test, two asterisks, P , 0.01; three asterisks, P , 0.001; four asterisks, P , 0.0001. All results were replicated in at least three independent experiments.
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transplantation establishes them as promising candidates for in vivo modelling and autologous therapy of human liver diseases.
METHODS SUMMARY
Generation of iMPC-Heps from human fibroblasts. After retroviral transduction, human fibroblasts were grown in reprogramming initiation medium for 7 days, followed by culture in endoderm differentiation medium for 14-21 days. iMPC-EPC colonies were selected at day 21-28 and grown on mouse embryonic fibroblasts in endoderm expansion medium for 1-4 months. For differentiation into iMPC-Heps, iMPC-EPCs were first expanded for 4-5 days, followed by culture in hepatocyte differentiation medium for 4 days and then in hepatocyte maturation medium for 7-10 days. Media were supplemented with the growth factors and small molecules indicated in Fig. 1 . iMPC-Hep transplantation and analysis. iMPC-Heps were injected intrasplenically into FRG mice preconditioned by withdrawal of the drug 2-(2-nitro-4fluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) and retro-orbital injection of an adenovirus expressing urokinase plasminogen activator. Mice underwent repeated cycles of NTBC: absent for 7-10 days and present for 2-3 days. Liver repopulation was monitored by HSA enzyme-linked immunosorbent assay (ELISA). 
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METHODS
Generation of iMPC-EPCs from human fibroblasts. Human newborn fibroblasts (CRL-2097; ATCC) were cultured in a 10-cm tissue culture dish coated with 0.1% gelatin, and transduced twice with freshly produced retrovirus supernatants as described previously 12, 24 . For reprogramming, 10 4 transduced cells were seeded in a 10-cm tissue culture dish coated with 0.1% gelatin, and cultured for 7 days in reprogramming initiation medium (RIM) supplemented with 3 mM CHIR, 100 mM dilauroyl phosphatidylcholine (DLPC; Tocris), 0.1 mM sodium butyrate (NaB), 2 mM Parnate (Par), 0.5 mM RG108 (RG), 10 ng ml 21 epidermal growth factor (EGF) and 10 ng ml 21 basic fibroblast growth factor (bFGF), followed by culture for 14-21 days in endoderm differentiation medium (EDM) supplemented with 3 mM CHIR, 100 mM DLPC, 0.1 mM NaB, 2 mM Par, 0.5 mM RG and 100 ng ml 21 activin A. Reprogrammed colonies were picked at day 21-28 for expansion on passage 4 irradiated CF1 mouse embryonic fibroblasts (MEFs) in endoderm expansion medium (EEM) supplemented with 3 mM CHIR, 10 ng ml 21 EGF, 10 ng ml 21 bFGF and 0.5 mM A83, and were passaged at a ratio of 1:4-1:6 after dissociation with Accutase.
To prevent cell death, 0.5 mM thiazovivin was added to the medium in the first 12-24 h after each passage. RIM consists of DMEM/F12 medium, 10% knockout serum replacement (KSR), 5% ES-FBS, 1% Glutamax, 1% non-essential amino acids (NEAA), 1% penicillin/streptomycin (P/S) and 0.1 mM 2-mercaptoethanol (2-ME); EDM consists of advanced RPMI, 2% ES-FBS, 1% Glutamax, 1% NEAA, 1% P/S and 0.1 mM 2-ME; EEM consists of DMEM, 1% Glutamax, 0.5 3 N2, 0.5 3 B27 (without vitamin A), 5 mg ml 21 BSA and 1% P/S. All cell culture reagents were from Invitrogen and all chemicals and all growth factors were from Stemgent except where otherwise specified. Generation of iMPC-Heps from iMPC-EPCs. The principles of the protocol were adopted from previously published protocols 1,25 , modified and improved by the addition of small molecules. In brief, iMPC-EPCs were cultured for 4-5 days in EEM, for 4 days in hepatocyte differentiation medium (HDM) supplemented with 20 ng ml 21 bFGF, 20 ng ml 21 BMP4 (Stemgent), 0.1 mM Dex (Sigma-Aldrich) and 0.5 mM A83 (Stemgent), and finally for 7-10 days in hepatocyte maturation medium (HMM), consisting of HCM (Hepatocyte Culture Medium; Lonza) supplemented with 0.5 mM A83, 0.1 mM Dex, 20 ng ml 21 HGF (R&D), 20 ng ml 21 OSM (R&D) and 0.1 mM C-E (EMD Millipore). iMPC-Heps were passaged at a ratio of 1:4 using Accutase, and cultured in HCM until use for analysis or transplantation. HDM consists of DMEM, 1% Glutamax, 1 3 B27 and 1% P/S. Generation of DECs and GECs from ESCs. H9 ESCs (WiCell WA09) were cultured for 3 days on Matrigel (BD; 1:50 dilution)-coated six-well plates in Essential 8 Medium (Invitrogen). For endoderm differentiation, cells were cultured for 1 day in RPMI 1640, 1% Glutamax, 1% P/S, 100 ng ml 21 activin A and 3 mM CHIR, for 2 days in RPMI 1640, 1% Glutamax, 0.2% ES-FBS, 1% P/S and 100 ng ml 21 activin A, and finally for 3 days in DMEM/F12, 1% Glutamax, 2% ES-FBS, 1% P/S, 25 ng ml 21 FGF7 (R&D) and 25 ng ml 21 FGF10 (R&D). As reported previously 17 , cell populations at days 3 and 6 of differentiation were considered ESC-DECs and ESC-GECs, respectively. Generation of iPSC-Heps. Normal donor iPSCs grown on passage 3 irradiated CF1 MEFs were differentiated into DECs for 5-7 days as described previously 3 , using insulin-free 1 3 B27 (Invitrogen) instead of FBS. DECs were differentiated directly (without splitting) into iPSC-Heps by culture for 5 days in IMDM (Invitrogen) containing 1 3 B27 with insulin (Invitrogen), 1% Glutamax, 0.3 mM monothioglycerol (Sigma-Aldrich), 1% Antibiotic-Antimycotic (Invitrogen), 0.126 U ml 21 human insulin (Sigma-Aldrich), 10 ng ml 21 bFGF, 20 ng ml 21 BMP4 and 100 nM Dex. Maturation was continued for 15-20 days in the same medium additionally supplemented with 20 ng ml 21 HGF before switching for 5-7 days to HCM supplemented with 20 ng ml 21 HGF and 20 ng ml 21 OSM, similar to previously reported protocols 1, 3 . All growth factors were purchased from R&D. Reprogramming using temporally controlled transcription factor overexpression. Doxycycline-inducible lentiviruses carrying the reprogramming factors OCT4, SOX2 and KLF4 were described previously 26 . CRL-2097 fibroblasts were cultured in a 10-cm tissue culture dish coated with 0.1% gelatin, and transduced twice with freshly produced lentivirus supernatants as described previously 13 . For iMPC-EPC reprogramming, 10 4 transduced cells were seeded in a 10-cm tissue culture dish coated with 0.1% gelatin, and cultured for 7, 10 or 14 days in RIM supplemented with 4 mg ml 21 doxycycline, 3 mM CHIR, 100 mM DLPC, 0.1 mM NaB, 2 mM Par and 0.5 mM RG, followed by culture for 14, 11 or 7 days, respectively, in EDM supplemented with 3 mM CHIR, 100 mM DLPC, 0.1 mM NaB, 2 mM Par, 0.5 mM RG and 100 ng ml 21 activin A. For iPSC reprogramming, 10 4 transduced cells were seeded in a 10-cm tissue culture dish, and cultured for 7, 10 or 14 days in RIM supplemented with 4 mg ml 21 doxycycline, 3 mM CHIR, 100 mM DLPC, 0.1 mM NaB, 2 mM Par and 0.5 mM RG, followed by treatment for 23, 20 or 16 days, respectively, with iPSC medium (iPSCM). iPSCM consists of DMEM/F12, 1% Glutamax, 20% KSR, 1% NEAA, 1% P/S, 0.1 mM 2-ME and 10 ng ml 21 bFGF.
Generation of iPSC-Heps with the iMPC-EPC/Hep generation protocol. Normal donor iPSCs were grown for 3 days on passage 4 irradiated CF1 MEFs in iPSCM and then for 2 weeks in EDM supplemented with 3 mM CHIR, 100 mM DLPC, 0.1 mM NaB, 2 mM Par, 0.5 mM RG and 100 ng ml 21 activin A. After dissociation with Accutase, the resulting cells were passaged at a ratio of 1:4 onto irradiated CF1 MEFs and cultured for 4 days in EEM. Next, the cells were cultured for 4 days in HDM supplemented with 20 ng ml 21 bFGF, 20 ng ml 21 BMP4, 0.1 mM Dex and 0.5 mM A83, and finally for a further 10 days in HMM, consisting of HCM supplemented with 0.5 mM A83, 0.1 mM Dex, 20 ng ml 21 HGF, 20 ng ml 21 OSM and 0.1 mM C-E. Cell immunostaining. Standard immunostaining was performed as reported previously 13 . Primary antibodies were goat anti-SOX17 antibody (catalogue no. AF1924; R&D) diluted 1:1,000, rabbit anti-FOXA2 antibody (catalogue no. AB4125; Millipore) diluted 1:500, goat anti-FOXA2 antibody (catalogue no. AF2400; R&D) diluted 1:1,000, mouse anti-HNF4a antibody (catalogue no. PP-H1415-00; Perseus Proteomics) diluted 1:500, mouse anti-AAT antibody (catalogue no. MA190438; Thermo Scientific) diluted 1:500, goat anti-PDX1 antibody (catalogue no. AF2419; R&D) diluted 1:1,000, goat anti-OCT4 antibody (catalogue no. sc-8629; Santa Cruz Biotechnology) diluted 1:500, rabbit anti-NANOG antibody (catalogue no. ab80892; Abcam) diluted 1:500, mouse anti-AFP antibody (catalogue no. A8452; Sigma-Aldrich) diluted 1:500, mouse anti-CK18 antibody (catalogue no. ab82254; Abcam) diluted 1:500, and goat anti-ALB antibody (catalogue no. A80-129A; Bethyl) diluted 1:500. Secondary antibodies were Alexa Fluor 488/555 donkey anti-mouse or antirabbit or anti-goat IgG (diluted 1:1,000) (Invitrogen). Nuclei were revealed by staining with Hoechst 33258 (Sigma-Aldrich). Images were captured with a Nikon Eclipse TE2000-U microscope. Flow cytometry. Cells were harvested by dissociation for 2-5 min with Accutase at 37 uC, and fixed for 10 min with 4% formaldehyde in D-PBS (Sigma-Aldrich) on ice. Afterwards, cells were washed five times with ice-cold Perm/Wash buffer (BD).
To remove undissociated cell clusters, cells were passed twice through 70-mm cell strainers (BD). Cells were immunostained on ice for 2 h with goat anti-FOXA2 antibody (catalogue no. AF2400; R&D) diluted 1:100, rabbit anti-NANOG antibody (catalogue no. ab80892; Abcam) diluted 1:20, mouse anti-HNF4a antibody (catalogue no. PP-H1415-00; Perseus Proteomics) diluted 1:100, goat anti-ALB antibody (catalogue no. A80-129A; Bethyl) diluted 1:100, mouse anti-CK18 antibody (catalogue no. ab82254; Abcam) diluted 1:100, or phycoerythrin-conjugated mouse anti-TRA-1-60 antibody (catalogue no. 330609; Biolegend) diluted 1:50. To determine background levels of each immunostaining, cell aliquots were incubated with the respective isotype control antibodies. After immunostaining, cells were washed five times with Perm/Wash buffer. Cells were then incubated on ice for 1 h with Alexa Fluor 488-conjugated or Alexa Fluor 555-conjugated secondary antibodies (Invitrogen) diluted 1:500. Afterwards, cells were washed five times with Perm/ Wash buffer. Finally, cells were resuspended in 0.5 ml of ice-cold D-PBS supplemented with 2% FBS, and flow cytometry was performed on a FACSCalibur system using CellQuest software (BD). FlowJo software (Tree Star) was used to analyse the data. qRT-PCR. Total RNA was extracted using the miRNeasy Mini Kit (Qiagen) or RNeasy Plus Mini Kit in combination with QIAshredder (Qiagen). First-strand reverse transcription was performed with 0.5-1.0 mg of RNA using the iScript cDNA Synthesis Kit (Bio-Rad) or qScript cDNA Supermix (Quanta Biosciences). qRT-PCR was performed with PerfeCTa SYBR Green SuperMix (Quanta) or iQ SYBR Green Supermix (Bio-Rad) on an Applied Biosciences ViiA 7 Real-Time PCR System (Invitrogen). aHeps purchased from Yecuris or the Liver Tissue Cell Distribution System (NIH) and fHeps obtained from StemExpress were shipped overnight in suspension, centrifuged for 5 min at 300g immediately after arrival, and stored as cell pellets at 280 uC before RNA extraction. Primer sequences are shown in Supplementary Table 3 . Human gene-specific primers were derived from previous publications 8, [27] [28] [29] [30] [31] [32] [33] 
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Low-density lipoprotein (LDL) uptake assay. Dil-ac-LDL (Invitrogen) was added to the medium (5 ml per well of a 12-well plate); 2 h later, the cells were washed with medium and imaged by fluorescence microscopy. Urea production. Cell culture supernatant was collected and analysed with the QuantiChrom Urea Assay Kit (BioAssay Systems) in accordance with the manufacturer's instructions. ALB ELISA of cell culture supernatants. The amount of ALB in cell culture supernatants was determined using a human-specific ALB ELISA kit (catalogue no. EA3201-1; Assaypro) in accordance with the manufacturer's instructions. Cells were cultured in HMM for 24 h, and the supernatant was collected for analysis. Control aHeps (HMCPMS lot no. Hu8138; Life Technologies) were analysed 24 h after plating. Mice and transplantation. Procedures involving mice were approved by the Institutional Animal Care and Use Committee at the University of California San Francisco. Immune-deficient, fumarylacetoacetate hydrolase (Fah)-deficient mice lacking B, T and natural killer cells due to disruption of Rag2 and Il2rg-socalled FRG mice-were used as recipients 8 . Mice were maintained on NTBC (Yecuris) in the drinking water at 16 mg l 21 . One day before transplantation, mice were taken off NTBC. An adenovirus expressing urokinase plasminogen activator (Ad-uPA) was used for liver preconditioning 34 . Ad-uPA was delivered by retroorbital injection 24 h before transplantation at a dose of 5 3 10 7 plaque-forming units (PFU) per g body weight. Transplantation was performed by intrasplenic injection through a left-flank incision under isoflurane anaesthesia and buprenorphine analgesia. After transplantation, mice received NTBC in the drinking water in cycles consisting of 7-10 days with NTBC absent and 2-3 days with NTBC present at 4 mg l 21 . For surgical prophylaxis, 5 mg of Naxcel (Pfizer) was given by intraperitoneal injection immediately before transplantation, and daily for 7 days. Because of the immune deficiency of the mice, all received additional prophylactic antibiotic treatment with Ciprofloxacin (Hospira) at 0.25 mg ml 21 in the drinking water for 7 days, then trimethoprim/sulfamethoxazole (TMP/SMX; Sigma-Aldrich) in the drinking water at 0.2 g l 21 TMP and 1 g l 21 SMX continuously. aHeps for transplantation were purchased from Yecuris, shipped overnight in suspension and transplanted into recipient mice immediately after arrival. HSA ELISA. HSA levels were determined with the Human Albumin ELISA Quantitation Set (catalogue no. E80-129; Bethyl). Blood (3 ml) drawn by tail clipping was immediately diluted 1:100 in sample diluent; HSA concentration was determined by ELISA with a human-specific ALB antibody. Tissue immunostaining. Liver tissue harvested from recipient mice was frozen immediately in optimum cutting temperature (OCT) compound (Tissue-Tek; Sakura Finetek) or fixed overnight in 4% paraformaldehyde (Sigma-Aldrich) or 10% formalin (Sigma-Aldrich) at 4 uC. Tissues for frozen sections were cryoprotected in 30% sucrose (Sigma-Aldrich) before embedding and freezing in OCT. For paraffin embedding, tissues were preserved in 70% ethanol before processing. Frozen tissues were cut with a Leica 3050S Cryostat into 5-7-mm sections, air dried, and stored at 220 uC before staining. Tissue sections were stained with rabbit anti-FAH antibody (gift from R. Quantification of liver repopulation. Overall liver repopulation with transplanted iMPC-Heps was determined by measuring the area of recipient mouse liver sections composed of iMPC-Heps by ALB and FAH immunostaining relative to the total area of liver tissue. Sections were taken from six separate pieces of liver tissue from different parts of the recipient's liver. Areas were calculated with ImageJ software (NIH). The number of iMPC-Heps per nodule was estimated by using a previously described method 35, 37 . In brief, the number of iMPC-Heps present in the two-dimensional section showing the widest diameter of a repopulating nodule was multiplied by a previously determined correction factor to estimate the total number of hepatocytes comprising the three-dimensional nodule. In vivo CYP2D6 activity analysis. Plasma samples (40 ml) were obtained by retroorbital blood draw at 0, 1 and 2 h after administration of debrisoquine (Enzo Life Sciences) at 2 mg per kg body weight in water by gavage. A standard curve was created by serial dilution of a solution with equal amounts of debrisoquine and 4-hydroxy-debrisoquine (Santa Cruz Biotechnology), using a 1:1 acetonitrile:water solvent mixture. Aliquots of standard solutions not exceeding 5 ml in size were added to 100 ml of Swiss Webster K 2 EDTA mouse plasma (Bioreclamation) to create plasma standards with concentrations from 0.01 to 50 mM. All plasma samples were precipitated with four volumes of cold acetonitrile, vortex-mixed for 1 min and, after standing for 30 min at 220 uC, centrifuged for 5 min at 13,000g. The supernatants separated into upper and lower phases; the smaller lower phases were used in the analyses. Debrisoquine and 4-hydroxy-debrisoquine were measured by LC-MS/MS with an API4000 MS/MS mass spectrometer (AB Sciex) with electrospray ionization in the positive-ion mode. They were detected with the transitions 176.1R134.1 and 192.1R132.1 m/z. Instrumental settings were 46 and 41 V for DP (declustering potential), and 25 and 27 eV for CE (collision energy), respectively. Settings in common for both analytes were CXP (collision cell exit potential) 5 8 V, EP (entrance potential) 5 10 V, CAD (collision gas) 5 12 lbf in 22 , IS (ion spray voltage) 5 5,500 V, temperature 5 600 uC, CUR (curtain gas) 5 35 lbf in 22 and GS1 (ion source nebulizer gas) 5 GS2 (ion source heater gas) 5 50 lbf in 22 . The LC method employed a 50 mm 3 4.6 mm C 18 , 5-mm, 100-Å Kinetex column (Phenomenex) and a binary mobile phase with A 5 15% methanol:water (with 160 mg l 21 NH 4 CH 3 CO 2 , 0.1% formic acid and 0.1% acetonitrile) and B 5 100% methanol (with the same additions). Flow rate was 0.5 ml min 21 . The gradient used was as follows: 0-1 min, 0% B; 1-4 min, linear ramp to 100% B; 4-5 min, 100% B; 5-5.5 min, linear ramp to 0% B; 5.5-8.0 min, 0% B. Injection size was 3 ml, and retentions were 2.94 min for 4-hydroxy-debrisoquine and 3.85 min for debrisoquine.
Survival studies. To model acute liver failure, FRG mice were taken off NTBC and injected with Ad-uPA (5 3 10 7 PFU per g body weight) 1 day before transplantation. Mice were kept off NTBC, and survival was recorded daily. To model chronic liver failure, mice were also taken off NTBC and injected with Ad-uPA (5 3 10 7 PFU per g body weight) 1 day before transplantation, but 7 days after transplantation NTBC was reinstated at a dose of 4 mg l 21 . From there on, mice were subjected to repeated cycles consisting of 10 days with NTBC absent and 3 days with NTBC present. Survival was recorded twice a week. For both liver failure models, 8-12-week-old FRG mice were used. Littermates were distributed between experimental and control groups. Male and female mice were distributed equally between groups. Blinding was not done. All transplanted mice were included in the analysis with the exception of mice that died within 24 h after transplantation, which was considered a complication of the surgery, because Fah deficiency is known to take longer to unfold 35 . Statistical analysis. The s.d. and s.e.m. were calculated from the average of at least three biological replicates unless otherwise specified. Data were compared between experimental and control groups by using Student's t-test (unpaired, two-tailed). Survival was compared by using the Mantel-Cox log-rank test. A P value of less than 0.05 was considered significant. 
LETTER RESEARCH
